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Choosing not to know: accounts of non-engagement with pre-symptomatic testing 1 
for Machado-Joseph disease 2 
 3 
ABSTRACT  4 
This paper reports accounts from people at-risk for, or affected by, Machado-Joseph 5 
disease, and their family members, about their decisions not to seek pre-symptomatic 6 
testing, therefore remaining (for the time) uninformed about their genetic status. We 7 
draw on individual and family semi-structured interviews with participants recruited 8 
through a national patient’s association (n=25). Qualitative thematic analysis revealed 9 
three main categories of accounts: (1) justifying the decision “not to know”, because 10 
either no clinical benefit was expected or predictive knowledge was anticipated as 11 
psychologically burdensome; (2) prioritizing everyday life, maintaining hope and the 12 
goal of living a valid life; and (3) the wish to know: ambivalence and conflict within the 13 
family. Findings suggest the value of genetic information is often questioned when no 14 
effective treatment or cure is available; and that people have different tolerance 15 
thresholds for predictive information, and this impacts individuals within the family 16 
differently. We discuss this in the context of the making of “responsible” decisions, and 17 
of the tensions that may arise within families between the best interests or wishes of a 18 
person and those of other family members. We hope this will clarify the reasoning of 19 
those who opt for non-engagement with medical genetic services and, more specifically, 20 
pre-symptomatic testing. Further, we hope it will be relevant for the provision of genetic 21 
counselling and psychosocial support to such families. 22 
 23 
Keywords: predictive testing, genetic risk, Portugal, Machado-Joseph disease, 24 
spinocerebellar ataxia type 3, late-onset neurological diseases. 25 
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 26 
INTRODUCTION 27 
Decisions to undergo pre-symptomatic testing (PST) for highly-penetrant, late-onset 28 
neurological diseases (LONDs) are commonly permeated by great psychosocial 29 
complexity1. Genetic counselling and PST are standard procedures offered to 30 
individuals at-risk for LONDs, in accordance with guidelines that might be applied in 31 
different contexts and for a range of diseases2. For some, PST can provide helpful 32 
information, namely clinical surveillance for early signs of the disease and early 33 
treatment of complications; however, for severely incapacitating LONDs, such as 34 
Machado-Joseph disease (MJD) and when no medical intervention is currently 35 
available, PST provides information without leading to any direct clinical benefit.  36 
MJD (also known as spinocerebellar ataxia type 3, SCA3) is a dominantly inherited, 37 
multisystem degenerative disorder (average age-of-onset: 40.5 years); symptoms 38 
generally include progressive motor difficulties, incoordination of gait, speech and fine 39 
movements of the hands, involuntary eye movements, and, later on, complete loss of 40 
autonomy in daily living3. MJD is the most common SCA worldwide; its highest 41 
frequency is described in Brazil, Portugal and China4. In Portugal, MJD has an overall 42 
prevalence of 3.1:100,000, but some clusters have higher rates (835.2 in Flores and 27.1 43 
in São Miguel, Azorean islands; and 14.4:100,000 in central areas of the mainland, 44 
especially along the Tagus valley)5. 45 
Research indicates that relatively few individuals at-risk for LONDs request PST. For 46 
example, in Brazil, only 9% of the estimated population at 50% risk for MJD completed 47 
PST6; uptake of PST for Huntington disease (HD) in the UK was estimated as 17.4%7, 48 
while in Cuba the uptake of PST for SCA2 was estimated to be 24.9%8. While the 49 
psychological and social understanding of the experiences and consequences of PST for 50 
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MJD, is well documented9-14, far less is known about those who decide not to undertake 51 
PST. Most psychosocial studies have been conducted in the context of PST, and thus 52 
recruit self-selected individuals already attending genetics clinics; it is far more difficult 53 
to access a representative, unselected population. One factor that may make those at risk 54 
reluctant to take part in research and to contact clinical genetics services is their wish 55 
(and right) not to know their genetic status or not to be reminded of their risks too often. 56 
Much previous research has focused on at-risk subjects who request PST but then 57 
decide not to proceed15,16; or on what is reported second-hand by those who proceed 58 
with testing, about their relatives who chose not to know.  59 
To our knowledge, only one study has addressed those who chose not to undertake PST 60 
for MJD: an ethnographic study reported concerns among Brazilian MJD families with 61 
the emotional impact of a positive test result, including that it could hasten evolution of 62 
symptoms, and prevent attaining normative life goals17. Other research reported how 63 
individuals who made no attempts to seek PST for HD may be judged negatively by 64 
relatives and are often asked to justify their decision18; this creates tension in family 65 
relationships, as others regard it as a moral imperative to do so. Comparable findings 66 
have been reported in a family with limb-girdle muscular distrophy19 and a kinship with 67 
Lynch syndrome (LS)20. A recent study described decliners of predictive testing for LS 68 
(which has the possibility of medical follow-up and preventive measures) as ranging 69 
from being uninformed to declining testing at all, not perceiving benefits and fearing 70 
negative consequences21. Taken together, these findings suggest that ‘decliners’ or 71 
‘non-requesters’ have different positionings towards genetic information and make their 72 
decisions within a different logic and morality, when compared with each other or with 73 
those who have engaged with genetic testing. Thus, circumstances around non-74 
engagement with PST for MJD may not have been adequately reported so far. This 75 
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paper aims to contribute to this knowledge, by reporting accounts from persons at-risk 76 
of, or affected by, MJD and their family members, about their (current or past) decisions 77 
of not seeking PST, or their opinions concerning relatives who decided not to undertake 78 
PST. 79 
 80 
METHODS 81 
This exploratory, qualitative study was drawn from a larger empirical study examining 82 
processes of communication of information about genetic risks in families affected by 83 
LONDs, including familial amyloid polyneuropathy TTR Val30Met, HD and MJD22-24. 84 
We present here the sub-corpus of data focusing on decisions of non-engagement with 85 
PST, a relevant theme that emerged during that analysis, drawing on data from families 86 
with MJD (the majority in that study).  87 
 88 
Recruitment  89 
Following approval by the IBMC Human Ethics Committee, participants were recruited 90 
through the national patients’ association for hereditary ataxias. Inclusion criteria 91 
involved persons potentially competent to give consent, either affected or at-risk for 92 
MJD, or their family members. A leaflet with information about the study and its aims, 93 
inviting people for an interview, was circulated in newsletters and website of the 94 
association and in social media, asking those potentially willing to participate to contact 95 
the researcher. The patients’ association also made the study known at members’ 96 
meetings; those agreeing to participate authorized their contact information to be sent to 97 
the main researcher, who then contacted them. Snowball sampling25 was also adopted 98 
by asking participants whether they knew other persons or families that might be 99 
interested to participate. 100 
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 101 
Participants  102 
Data pertaining to non-engagement with PST involved a sub-corpus of 12 interviews, 103 
out of 32; of those, 8 interviews involved participants from MJD families, 6 of which 104 
included multiple family members (i.e., a joint interview with relatives and non-105 
biological family members). Overall, this study comprised 25 participants (subsequent 106 
contact with two potential participants failed), all of white-European ethnic background 107 
(cf. Table 1 for socio-demographic and disease-related information).  108 
[INSERT TABLE 1 ABOUT HERE] 109 
 110 
Data collection 111 
Interviews were conducted between April 2014 and June 2017, at the participant’s home 112 
(5), in a primary health centre (2), or in a public space (1), as chosen by them. All were 113 
conducted by ÁM, after written consent had been obtained. Interviews were audiotaped 114 
with the participants’ consent, transcribed and translated into English. Each lasted 115 
approximately one hour. Social, demographic and disease-related data were collected, 116 
followed by an open question about experiences of living with, or at risk of, the disease. 117 
Interviews centred on the value of genetic information, motivations and engagement 118 
with PST, and experiences of talking to relatives about test results or genetic risks more 119 
broadly. The focus was on what issues they found important and how they expressed 120 
and elaborated their arguments. Case summaries were created, highlighting the most 121 
relevant aspects, contextual observations and emerging ideas about topics to discuss in 122 
future interviews26. 123 
 124 
Data analysis  125 
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The transcribed interviews were analysed thematically using coding and the method of 126 
constant comparison26. Each transcript and the corresponding interview notes were read 127 
repeatedly and the key topics addressed were mapped out. These were then coded, by 128 
breaking them down into small sections to identify the most significant items. Next, 129 
coded data were constantly compared within and among transcripts, to identify any 130 
likely connections. Recognized themes relating to non-engagement with PST were then 131 
grouped together in an iterative process, according to their main features and meaning. 132 
Findings were then interpreted with reference to a broad psychosocial framework aimed 133 
at understanding the interpersonal context that surrounds individuals and families, as 134 
they live with, or at risk for, an inherited disease27-29. 135 
 136 
RESULTS 137 
Each theme is presented (with data extracts) to illustrate key points. Quotations are 138 
accompanied by a code for the participants (consecutive lettering, to protect 139 
confidentiality), age and sex (F, female; M, male), as well as disease-related features. 140 
Content in square brackets is used to add intelligibility to the participant’s quote; 141 
ellipsis with a single/double dot means a brief/extended pause; underscored text 142 
indicates louder, more emphatic speech; “...” indicates some words or sentences were 143 
omitted; and “~” indicates overlapping speech. 144 
 145 
(1) Justifying the decision “not-to-know”, because either no clinical benefit was 146 
expected or predictive knowledge was anticipated as psychologically burdensome  147 
This theme was expressed in seven interviews and focuses on the reasons given by 148 
participants for remaining uninformed about their genetic status. In general, participants 149 
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framed access to presymptomatic genetic information as being pointless, because no 150 
effective or acceptable treatment or palliation of symptoms was yet available for their 151 
family’s disease:  152 
“I preferred to wait and see, because there is nothing one could do about it. If there were a treatment, 153 
a drug, something (.) I only did the analysis last year, because I started to feel my legs sort of tight (.) 154 
to lose balance and falling (.) I wanted to postpone it until I could not stand on my own any more”. [A, 155 
49y, M, clinically affected (mild symptoms); two children] 156 
Several participants framed engagement with genetic knowledge, although removing 157 
uncertainty, as having the potential to become seriously burdensome. Therefore, they 158 
preferred to live free from the psychological concerns posed by a pre-symptomatic 159 
diagosis of an impending severe disease: 160 
“I rather not think about it, I really prefer not to know. I don’t want to have that constantly popping 161 
up in my head (..) I prefer to deal with one thing at a time”. [B, 30y, M, at 50% risk; 56y father 162 
severely affected] 163 
Next, C describes how her decision not to undertake PST was also based on family 164 
members’ experiences and reactions after knowing their results; by avoiding genetic 165 
testing and its potentially destabilizing knowledge, not only does she seek to preserve 166 
her own psychological wellbeing, but also that of her daughter:  167 
“My sister decided to do the test and everything started to change: she sold her house and moved to a 168 
ground floor apartment,taking all decisions thinking that the future would come up badly and quick. 169 
It’s just too frightening (.) I prefer to live the here and now (..) And I think: if I do it I’ll start to over-170 
think it all the time, like ‘I’ll get it, I’ll get it!’ It happened to one of my cousins; she started to feel 171 
psychologically affected, you know (.) really down […] And my daughter, she’d probably start to 172 
think she would have it as well and would miss the best years of her youth with this worry.” [C, 52y, 173 
F, 50% risk; one daughter] 174 
 175 
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(2) Prioritizing everyday life, maintaining hope and the goal of living a normal life 176 
This theme was widely shared among participants and shows how they articulated 177 
lifeworld considerations while discussing their options. Some participants anticipated 178 
that the potential worry regarding future health risks, following a “positive” test result, 179 
would impair their capacity to focus on their everyday life. Other participants claim the 180 
need to be psychologically “available” (i.e., free from the emotional unrest caused by a 181 
potentially adverse pre-symptomatic result) to assure caregiving for those affected, as 182 
well as parenting their children: 183 
“I don’t think much about the disease (..) I really make an effort to avoid thinking about it. Now, I am 184 
very keen to be a father, you know (.) I just want to be a good father, it’s my first [baby], I’m focused 185 
on that.” [B, 30y, M, at 50% risk; 56y father severely affected] 186 
When asked if he would undertake PST if his (at-risk) mother had tested “positive”, D 187 
described his reasoning: 188 
“I guess I wouldn’t, no. I’d see how it’d go (..) We just can’t give up our lives! E [referring to his 59y 189 
uncle, severely affected, present at this family interview] is staying at a day-care facility (.) we need 190 
to stay united, and keep our jobs, so we can give him the best care we can; his brother, my other 191 
uncle, is staying at home because they can’t afford the day-care centre, so they need to stay with him, 192 
to take care for him. It’s like one step at a time.” [D, 41y, M, non-carrier; 2 children] 193 
F describes the case of his wife, who had not requested PST and has preferred to face 194 
the consequences of the disease only as they have arisen. In doing so, they framed this 195 
decision as an attempt to live in hope while they were a young couple: 196 
“She [G, wife] hasn’t had the test as she rather wanted to live day by day … and I think it was right, I 197 
agreed all along (.) One can’t always be thinking about the worst, can we? When we got married … 198 
people used to say ‘watch it, her mother has it and she [G] might have it too!’; but at that time you 199 
just want to move ahead, instead of not having a life, right?” [F, 54y, M, husband of G, 48y, F, 200 
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severely affected; no children] 201 
 202 
(3) The wish to know: ambivalence and conflict within the family 203 
Lastly, this theme describes considerations against deciding “not-to-know” and how it 204 
involved ambivalence and conflicting views within the family; it was addressed in about 205 
half of the interviews. Some participants described situations that would make them 206 
consider undertaking PST. These exceptions to their decision not-to-know were often 207 
framed for the sake of their children, as it could inform their reproductive decisions: 208 
C: “When she [H, daughter] wants to have children, then I’ll be happy to do the test, that’s different. 209 
When another life is at stake you need to be sure. At that time, I didn’t know anything about this, if I 210 
knew I would have done it”. ~ 211 
~ H:  “Honestly, I don’t think much about it. Of course, it’s important to know what you can count on 212 
in the future, but I guess that’s not a priority at this point in my life (.) Maybe when I decide I want to 213 
have a baby (..) It makes sense to be cautious: first to ask my mother to do the test, then to do it myself 214 
if needed, and then have the in vitro test [PGD]. [C, 52y, F, at 50% risk; one daughter, H, 20y, F, at 215 
25% risk] 216 
There were instances, however, where some ambivalence and tension were noticeable in 217 
managing the way non-engagement with PST was perceived within the family, 218 
especially in relation to decisions about reproduction. The next excerpts are from a 219 
family interview: 220 
I: “My nephews (.) they’re young, [they] are having children, they don’t want to know... of course it’s 221 
their life but that’s (..) I don’t think it’s right (.) one thing is when you have children before you know 222 
it; but when you know and you run the risk of having a child with the disease, that’s different.”~ 223 
~ D: “This isn’t like that, no, they deserve to be a whole family, to have a normal life! We can even be 224 
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looked as being selfish, but they have the right to be parents, to give grandchildren to their parents, 225 
and so on, no matter what it may come to in the future. They deserve to have a family!” 226 
E: “They’re doing right, they have time to know (..) what’s the point of knowing when you’re young 227 
anyway? (..) I’ve worked all my life (.) until I couldn’t do it anymore (..) they shouldn’t get stuck by 228 
that.” [I, 63y, F, non-carrier; three sons; D, 41y, M, son of I, non-carrier; 2 children; E, 59y, M, 229 
severely affected, brother of I; two sons] 230 
There were also accounts that more explicitly showed criticism towards relatives’ 231 
decisions not to undertake PST. These emphasize mainly the potential benefits of 232 
genetic knowledge to the planning of offspring’s lives: 233 
“He [ex-partner, at 50% risk for MJD] never wanted to know. I have been telling him he should do the 234 
test ever since, but he always preferred to avoid facing it (..) Now we’re divorced, and I’d like to know 235 
whether my children might have it or not, it’s a matter of organizing our life. He [looking at the older 236 
son, aged 11] already asks about it. I don’t want to live hiding this from them. He understands what 237 
this is all about. You can only be prepared for something if you have the chance to know it in advance, 238 
right?” [J, 35y, F; two children at 25% risk]  239 
 240 
DISCUSSION 241 
This is one of few studies exploring non-engagement with PST outside the usual 242 
cohorts seen in genetic counselling research. We report on individuals at-risk or affected 243 
by MJD about their decisions not to seek PST, therefore having remained uninformed 244 
about their genetic status. Accounts were made by participants about themselves or 245 
about family members, or made about them by other relatives. Decisions of non-246 
engagement with PST were either reported as being the participant’s current option or 247 
preferred option prior to becoming clinically affected. The main findings suggest that 248 
the value of genetic information is in the beholder and that (i) knowledge of genetic 249 
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information is questioned when no effective treatment or cure is available; (ii) people 250 
have different tolerance thresholds for predictive information (and this impacts 251 
individuals within the family differently); (iii) the making of “responsible” decisions 252 
involves trading potential health risks, against a corresponding burden to present life, 253 
including its anticipated psychosocial impact; and (iv) tensions may arise between the 254 
best interest or wishes of a patient and those of other family members. 255 
Participants were aware that PST could remove uncertainty as to whether they would be 256 
affected or not in the future; however, the incurable nature of MJD and lack of effective 257 
treatment, prompted most of these participants to perceive PST as being of little use. 258 
Under those circumstances, they also anticipated genetic knowledge as potentially 259 
burdensome. This is in line with research suggesting that participants tend to remain 260 
unengaged with predictive testing if it is perceived as too distressing30. Therefore, most 261 
participants acknowledged the possibility of undertaking a genetic (diagnostic) test in 262 
the future, only if or when they come to experience incipient symptoms. That was a 263 
preferred account for non-engagement with PST.  264 
Decisions to remain uninformed about one’s genetic status were also made to protect 265 
others in the family from this potentially destabilizing knowledge. As found in other 266 
studies, the assumption “to care not-to-know” was a compelling justification to avoid 267 
PST31. By deciding to avoid formal knowledge of their genetic status, these at-risk 268 
individuals seem not so much to actively reject PST, but rather choose to defer 269 
knowledge of their genetic status. This may represent an attempt to regain some sense of 270 
control over the impact that foreknowledge about their family’s disease may have on 271 
their lives. In doing so, they seem to prioritize the focus of their lives on everyday 272 
pressing concerns (such as parenting their children or caregiving for affected relatives), 273 
without the destabilizing knowledge of an impending disease. Others prioritized 274 
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keeping open the prospect of living a “valid”, worthwhile life, as that allowed them to 275 
preserve hope towards the future. These reflections ultimately evidence the participants’ 276 
personal and familial values, as to management of genetic risks17,21,28,29,31-33.  277 
Furthermore, our data provide accounts about other relatives’ non-engagement with 278 
PST. While the accounts we elicited were generally supportive of those who chose not 279 
to know, differences were noticeable among family members regarding the value of 280 
information and implications towards others, especially pointing out reproductive 281 
decisions. Some participants described possible future events that might lead them to 282 
change their mind, as when their adult offspring would like to know their genetic status 283 
or are considering having children, so that the disease would not be passed down to the 284 
next generation. As such, those participants recognized some utility of their predictive 285 
genetic information, presenting themselves as responsible parents31-33; however, there 286 
was also criticism and blame, particularly directed towards at-risk relatives who had 287 
opted to pursue reproduction irrespective of the risk of transmitting the disease to 288 
offspring. This allocation of blame may represent a dominant moral consensus that sees 289 
engagement with genetic services as the morally sound way to conduct life in the 290 
presence of genetic risks31-34.  291 
The great majority of participants – at least overtly, on the surface – did not seem to 292 
regard non-engagement in genetics as something detrimental, irresponsible or immoral. 293 
This is in contrast to previous studies focusing on other untreatable conditions17,18,31-33. 294 
In fact, some accounts framed the wish to protect family members from being actors of 295 
potentially blameworthy actions. While this may be explained by the unsettling 296 
emotional effects that may be promoted by divergent test results, this exonerates them 297 
from any charge of irresponsibility in the management of their lives and their genetic 298 
risks34. This suggests that the notion of genetic responsibility goes beyond the rational 299 
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calculation of the use of genetic information and engagement with formal genetics 300 
knowledge and healthcare, extending to lifeworld goals and personal and family values.  301 
 302 
Implications for practice and future research perspectives 303 
Although the numbers are small, this study may contribute to highlight some aspects of 304 
the thinking of at-risk individuals and their family members, particularly how they 305 
negotiate decisions regarding PST and access to genetic knowledge. This may be 306 
relevant to the practice of genetic counselling and the provision of psychosocial support 307 
to families, by bringing further insights into the decision-making process of at-risk 308 
family members. Future research would benefit from collecting data from larger 309 
samples, including persons in a wide range of social and demographic circumstances 310 
and from diverse geographies, which may generate additional understanding of this 311 
topic. Styles of dealing with health risks vary with social and cultural values, and so 312 
does the influence played by genetic technology in shaping morality and decisions in 313 
regard to genetic disease13,14,21,22 and testing35, and this certainly differs between regions 314 
and countries. 315 
People's decisions and accounts may change once effective and acceptable therapies are 316 
available (or people think they are imminent). To what extent do the dynamics of hope 317 
for those at risk and their family members prompt changes in their mode of reasoning 318 
and decision-making in relation to genetic testing? How may a sense of empowerment 319 
and engagement with genetic healthcare best be promoted among at-risk individuals, 320 
while acknowledging their personal and collective experiences and decisions managing 321 
genetic risks and family relationships? 322 
 323 
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Limitations of the study  324 
This study had a small data corpus and focused on Portuguese families with MJD, 325 
mostly living in the rural region of the Tagus valley (a high prevalence region) and its 326 
findings cannot be generalized. Therefore, conclusions may not apply to other 327 
populations or to other similar diseases. Also, we must consider that about one third of 328 
our participants did not complete high-school education, which may have impacted the 329 
findings. Finally, as participants were involved in snowball recruiting to the research, 330 
they may have invited to participate with them in an interview those family members 331 
with whom they anticipated less disagreement. They may also have felt somewhat 332 
inhibited in their statements due to the presence of other family members. 333 
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